FDA Approves Durvalumab For Limited-Stage Small Cell Lung Cancer; Recommended Durvalumab Dose Is 1,500 MG Every 4 Weeks For Patients With A Body Weight Of ≥30 KG; Approved Astrazeneca's Imfinzi For Adults With LS-SCLC Whose Disease Has Not Progressed...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.